Top Life Sciences Industry Players Celebrated at Prestigious Awards Ceremony

AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards

  • Industry Leadership Award: Professors Steve Wilton AO and Sue Fletcher AO

  • Company of the year: Telex Medications

  • Emerging Business of the Year: Fusetec

AusBiotech Life Sciences Legacy Award: Dr. Andrew Forrest AO and Nicola Forrest AO

PERTH, Australia, October 27, 2022 /PRNewswire/ — The illustrious Biotech Industry Achievement Awards were announced today at the AusBiotech 2022 National Conference in Perth – recognize outstanding contribution and achievement. The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards recognize innovative companies and individuals in australia world-class biotechnology, medical technology and healthcare sectors.

Dr Andrew Forrest AO and Nicola Forrest AO also received the AusBiotech Life Sciences Legacy Award in recognition of their generous and active support of Australian medical research and innovation in the life sciences.

Chairman and CEO of AusBiotech, Lorraine Chiroiusaid: “These prestigious awards are a celebration of the excellence in cutting-edge innovation that is happening across the country and the extraordinary progress that these people and companies have contributed to the health of Australians and the growth of the sector. .”

“Congratulations to the winners, who demonstrate what can be achieved when innovation, passion and drive are combined with the vision and leadership needed to bring new medicines, medical devices and other new technologies to patients.

Announcement of awards, Mrs Kathy ConnellSenior Director, External Partnership for Innovation, ANZ, Johnson & Johnson Innovation, said, “Johnson & Johnson Innovation is proud to sponsor these awards, and to celebrate and recognize these exceptional winners for their commitment to excellence in life science innovation. The discovery, development and commercialization of biomedical research requires a global effort from a diverse ecosystem comprising scientists, entrepreneurs, philanthropists and industry partners. This year’s winners represent contributions from Australia and we commend their work as they seek to advance healthcare for humanity around the world.”

Dr Forrest said: “We are passionate about finding ethical and sustainable solutions to a range of issues that impact people and the planet, and we believe that our commitment and passion, both in our philanthropic work that in the business investments we make, contribute to Making the world a better place.

“We support Australian research and business, and partnerships with people around the world to share information and accelerate the development of breakthrough therapies, life-changing medical products and treatments. We are investing in the future of Australian innovation in healthcare in a way that has never been done here before.”

Learn more about the 2022 winners

Industry Leadership Award, Professor Steve Wilton AO, Director of the Center for Molecular Medicine and Advanced Therapies and Foundation Chair in Molecular Therapies, Murdoch University and Director of the Perron Institute of Neurological Sciences and Translational Studies of Perth, WA; and Professor Sue Fletcher AO, Principal Investigator, Center for Molecular Medicine and Advanced Therapies, Murdoch University and Scientific Director, PYC Therapeutics Perth, WA.
Professors Steve Wilton and by Sue Fletcher The collaboration and pioneering research has resulted in the development of three FDA-approved “exon skipping” drugs that overcome specific genetic mutations that cause Duchenne muscular dystrophy (DMD).

Their contribution to australia the biotech industry spans more than 25 years, and their work on exon skipping induced by antisense oligomers highlights australia rare disease medical research and neuromuscular science on the map. The three drugs (Exondys 51, Vyondys 53 and Amondys 45) were developed at the Perron Institute of Neurological and Translational Sciences with the University of Western Australia and was marketed in partnership with the American company Sarepta Therapeutics.

Company of the Year: Telix Pharmaceuticals
melbourne-the biopharmaceutical company headquartered at Telix Pharmaceuticals Limited (Telix) focuses on the development and commercialization of diagnostic and therapeutic (“theranostics”) radiopharmaceuticals. Founded in 2015, Telix has taken its flagship product Illuccix®, a PET PSMA imaging agent for the detection and staging of prostate cancer, from an academic proof of concept to a commercially proven product in the space of three short years, with FDA and TGA approval obtained in late 2021 (now reimbursed in both markets), and Health Canada approval in October 2022.

Commercial launch of Iluccix® in the United States in April 2022Telix has since generated 50 million US dollars (A$73 million) in sales; in addition to Australiait now has business operations in the United States, Europe and Japan. The first patient was photographed in Australia in September 2022, and distribution in the United States grew rapidly with a network of more than 150 radiopharmacies nationwide; the total US addressable market for PET PSMA imaging for prostate cancer is estimated at US$1-1.5 billion per year. Telix has other theranostics for oncology and rare diseases progressing through the pipeline, with more than 20 Telix-sponsored, investigator-led clinical trials spanning Phases 1-3.

Emerging Company of the Year: Fusetec
Founded in 2017, Fusetec’s medical technology is already revolutionizing medical education globally. Thanks to its advanced additive manufacturing, Fusetec’s realistic and anatomically accurate bones, skin and muscles are used during surgical training and reduce the need for medical students, residents and surgeons to practice on real patients or extremely expensive corpses. These medical devices are made to order and can be designed and manufactured to simulate a specific pathology. Currently available are models in orthopaedics, otolaryngology, neurology and gynecology, with more surgical disciplines under development.

Fusetec has entered into global partnerships and opened a first clinic for advanced 3D surgical training in southern australia, creating 157 direct jobs in research, production and administration; it plans to create 800 additional indirect jobs in southern australia in the supply chain, medical tourism and higher education sectors.

AusBiotech Life Sciences Legacy Award: Dr. Andrew Forrest AO and Nicola Forrest AO
Dr. Andrew Forrest AO and Nicola Forrest AO have demonstrated a deep commitment to finding ethical and sustainable solutions to a range of global issues as diverse as childhood cancer, ending modern slavery and ocean conservation.

Among australia the most active philanthropists and investors, they have invested more than $2.6 billion since 2001 through the Minderoo Foundation which they co-chair.

Their commitment to improving equitable health outcomes and australia medical and biotechnology ecosystem through their philanthropic and investment activities, are proving transformational for the Australian life sciences industry.

Minderoo’s Collaborate Against Cancer initiative works with global partners to overcome the biggest barriers to cancer prevention, diagnosis and treatment. Through Minderoo, the Forrests are accelerating the research and discovery of breakthrough therapies to make world-class cancer care accessible to everyone, regardless of address or background. In 2020, Minderoo mounted a crucial response to the COVID-19 pandemic to cushion australia diagnostic testing capacity and stocks of personal protective equipment in times of critical need.

Beyond their philanthropy, the Forrest family’s Tarrarang Group has supported Australian life science companies and recently launched Tenmile, a $250 million venture capital fund dedicated to helping innovators and companies create and scale impactful health technologies and biotech solutions. Tenmile seeks to address unmet healthcare needs and develop an Australian health science and technology sector of global significance.


About AusBiotech

AusBiotech is australia biotechnology organization, working on behalf of its members for over 35 years to provide representation and services to promote the global growth of Australian biotechnology. AusBiotech is a well-connected network of over 3,000 members in the life sciences, including the therapeutics, medical technology (devices and diagnostics), food technology and agricultural sectors.



View original content to download multimedia:


Comments are closed.